RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: Evidences from a meta-analysis

Molecular Biology Reports

Volumn 39, Issue 3, 2012, Pages 2347-2353

  Wei, Bingbing ^a   Xu, Zhuoqun ^a   Ruan, Jun ^a   Zhu, Ming ^a   Jin, Ke ^a   Zhou, Deqi ^a   Yan, Zhiqiang ^a   Xuan, Feng ^a   Zhou, Hongyi ^a   Huang, Xing ^a   Zhang, Jian ^a   Lu, Peng ^a   Shao, Jianfeng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Polymorphism; Prostate cancer; RNASEL

Indexed keywords

ARGININE; ASPARTIC ACID; RIBONUCLEASE L;

ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC MODEL; HUMAN; MALE; ONCOGENE; POPULATION RESEARCH; PROSTATE CANCER; RISK ASSESSMENT; RNASEL GENE; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; ENDORIBONUCLEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION, MISSENSE; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK FACTORS;

EID: 84863822689     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0985-x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269
3. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG (2005) Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26:1170-1181
4. Silverman RH (2007) A scientific journey through the 2-5A/ RNase L system. Cytokine Growth Factor Rev 18:381-388
5. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA (2010) Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 31:1597-1603
6. Martinez-Fierro ML, Leach RJ, Gomez-Guerra LS, Garza-Guajardo R, Johnson-Pais T, Beuten J, Morales-Rodriguez IB, Hernandez-Ordonez MA, Calderon-Cardenas G, Ortiz-Lopez R, Rivas-Estilla AM, Ancer-Rodriguez J, Rojas-Martinez A (2010) Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 10:326
7. Agalliu I, Leanza SM, Smith L, Trent JM, Carpten JD, Bailey- Wilson JE, Burk RD (2010) Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate 70:1716-1727
8. Beuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, Leach RJ (2010) Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 19:588-599
9. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA (2009) Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 69:874-885
10. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M, Schlomm T (2008) Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 43:277-283
11. Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert- Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA (2008) Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate 68:1790-1797
12. Shea PR, Ishwad CS, Bunker CH, Patrick AL, Kuller LH, Ferrell RE (2008) RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans. Prostate 68:354-359
13. Cybulski C, Wokolorczyk D, Jakubowska A, Gliniewicz B, Sikorski A, Huzarski T, Debniak T, Narod SA, Lubinski J (2007) DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 79:44-49
14. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang WY, Isaacs WB, Platz EA (2007) RNASEL Arg462Gln polymorphism and prostate cancer in PLCO. Prostate 67:849-854
15. Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H (2006) RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 15:474-479
16. Nam RK, Zhang WW, Jewett MA, Trachtenberg J, Klotz LH, Emami M, Sugar L, Sweet J, Toi A, Narod SA (2005) The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 11:8391-8397
17. Noonan-Wheeler FC, Wu W, Roehl KA, Klim A, Haugen J, Suarez BK, Kibel AS (2006) Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 66:49-56
18. Maier C, Haeusler J, Herkommer K, Vesovic Z, Hoegel J, Vogel W, Paiss T (2005) Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 92:1159-1164
19. Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, Adami HO, Augustsson-Balter K, Gronberg H (2004) Genetic analysis of theRNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 10:7150-7156
20. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H (2003) Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 89:691-696
21. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2002) Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 71:116-123
22. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, Bailey-Wilson J, Trent J, Carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2002) Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70:1299-1304
23. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman- Bolton J, Clipp SL, Visvanathan K, Platz EA (2009) Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 20:1739-1751
24. Rennert H, Zeigler-Johnson C, Mittal RD, Tan YC, Sadowl CM, Edwards J, Finley MJ, Mandhani A, Mital B, Rebbeck TR (2008) Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. Urology 72:456-460
25. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
26. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
27. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
28. Huang Y, Li L, Yu L (2009) XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis 24:331-339
29. Zhu W, Wei BB, Shan X, Liu P (2010) 765G[C and 8473T[C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 37:277-288
30. Zhang J, Zhuo WL, Zheng Y, Zhang YS (2010) Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis. Med Oncol 27:540-546
31. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR (2009) XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 106:16351-1635